3 active not recruiting, 3 completed, 1 recruiting, 1 terminated. 6 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 2, Completed 2, Recruiting 1, Terminated 1 |
| Phase 1 | 3 | Active not recruiting 1, Recruiting 1, Terminated 1 |
Follow Stage IIIB Bladder Cancer AJCC v8: new trials by email Literature Review of Stage IIIB Bladder Cancer AJCC v8 trials Research Report on Stage IIIB Bladder Cancer AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer Quemliclustat, Biospecimen Collection, Computed Tomography - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 27 | 2026-10-20 | 2026-10-22 |
| Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy Biospecimen Collection, Bone Scan, Computed Tomography - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2022-07-07 | 2026-09-22 |
| Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Ipilimumab, Nivolumab, Tocilizumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 35 | 2021-09-23 | 2026-09-16 |
| ARID1A and/or KDM6A Mutation and CXCL13 Expression Diagnostic Laboratory Biomarker Analysis, Nivolumab, Relatlimab - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 6 | 2021-09-21 | 2026-10-06 |
| Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies Atezolizumab, Avelumab, Durvalumab - Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 19 | 2021-04-14 | 2026-04-30 |
| Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes Patient Monitoring, Questionnaire Administration - Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8, Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8 | Completed | City of Hope Medical Center | 22 | 2020-08-11 | 2026-10-14 | |
| Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer Avelumab, Cisplatin, Fluorouracil - Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8 | Phase 2 | Completed | Mayo Clinic | 2 | 2018-09-19 | 2023-01-06 |
| Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy Pembrolizumab - Stage I Bladder Cancer AJCC v8, Stage II Bladder Cancer AJCC v8 | Phase 2 | Completed | M.D. Anderson Cancer Center | 23 | 2018-01-11 | 2024-06-25 |
Urinary Bladder Neoplasms (8) · Ureteral Neoplasms (5) · Urethral Neoplasms (4) · Carcinoma, Renal Cell (2) · Carcinoma, Transitional Cell (2) · Lung Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Gastrointestinal Neoplasms (1) · Melanoma (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Prostatic Neoplasms (1) · Urogenital Neoplasms (1) · Uterine Cervical Neoplasms (1)
Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Male Urogenital Diseases (8) · Neoplasms by Site (8) · Urinary Bladder Diseases (8) · Urogenital Diseases (8) · Urologic Diseases (8) · Urologic Neoplasms (8) · Neoplasms (7) · Urogenital Neoplasms (7) · Neoplasms by Histologic Type (5) · Ureteral Diseases (5) · Carcinoma (4) · Neoplasms, Glandular and Epithelial (4) · Urethral Diseases (4)
Nivolumab (3) · pembrolizumab (3) · Disulfides (2) · Immunoglobulin G (2) · Radiation (2) · Radiotherapy (2) · Specimen Handling (2) · avelumab (2) · enfortumab vedotin (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Biopsy (1) · CTLA-4 Antigen (1) · Cisplatin (1) · Fluorouracil (1) · Ipilimumab (1)
M.D. Anderson Cancer Center (4) · City of Hope Medical Center (1) · Fred Hutchinson Cancer Center (1) · Mayo Clinic (1) · National Cancer Institute (NCI) (1)
United States (8) · Canada (1)
Laleh Melstrom (1) · Neema Navai (1) · Parminder Singh (1) · Rodabe Amaria, MD (1) · Rohit Jain (1) · Rosa Nadal Rios, MD, PhD (1) · Sangeeta Goswami (1) · Siqing Fu, MD, PHD (1)
PMID 35537412, PMID 37328287, PMID 40580957
P30CA033572 (1), UM1CA186644 (1)